Evidence map›Paper›PMID 41314473›Full record

ReviewVirologica Sinica2025

Antiviral agents for dengue virus.

Yinghan Jiang, Yanran Wang, Yaqun Xu, Yuxin Tian, Mengyuan Zhao, Chenguang Shen, Yang Yang, Minghui Yang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Virologica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yinghan JiangSchool of Interdisciplinary Science, Beijing Institute of Technology, Beijing 100081, China; School of Life Science, Beijing Institute of Technology, Beijing 100081, China; Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing 100081, China.
Yanran WangCapital Center for Children's Health, Capital Medical University, Beijing 100069, China.
Yaqun XuAdvanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology, Zhuhai 519088, China.
Yuxin TianSchool of Interdisciplinary Science, Beijing Institute of Technology, Beijing 100081, China; School of Life Science, Beijing Institute of Technology, Beijing 100081, China; Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing 100081, China.
Mengyuan ZhaoSchool of Interdisciplinary Science, Beijing Institute of Technology, Beijing 100081, China; School of Life Science, Beijing Institute of Technology, Beijing 100081, China; Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing 100081, China.
Chenguang ShenBSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research School of Public Health, Department of Laboratory Medicine, Zhujiang Hospital, Key Laboratory of Infectious Diseases Research in South China, Southern Medical University, Ministry of Education, Guangzhou 510280, China. Electronic address: a124965468@smu.edu.cn.
Yang YangNational Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen 518112, China. Electronic address: young@mail.sustech.edu.cn.
Minghui YangSchool of Interdisciplinary Science, Beijing Institute of Technology, Beijing 100081, China; School of Life Science, Beijing Institute of Technology, Beijing 100081, China; Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing 100081, China; Advanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology, Zhuhai 519088, China. Electronic address: yangmh17@bit.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dengue virus (DENV) is a mosquito-borne pathogen responsible for a spectrum of illnesses, including dengue fever, dengue hemorrhagic fever, and dengue shock syndrome. Nearly half of the global population is at risk of DENV infection, making it a pressing public health issue worldwide. The limited cross-protection among the four DENV serotypes (DENV1-4) and the phenomenon of antibody-dependent enhancement (ADE) have posed significant challenges to the development of effective dengue vaccines. Furthermore, there are currently no specific antiviral treatments available. This review provides an overview of DENV's key characteristics, clinical manifestations, and recent advancements in antiviral drug development- including the repurposing of approved drugs, peptide-based antiviral agents, therapeutic antibodies, natural products with antiviral potential, and host factor inhibitors- aiming to offer critical insights to inform strategies for managing and preventing dengue outbreaks.

Indexed as

Antiviral AgentsDengueDengue VirusAnimalsDrug RepositioningHumansAntiviral AgentsAntiviral agentsDengue virusFlavivirusPeptides drugs

Identifiers

PMID41314473
PMCPMC12826978

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.